Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

EP. 1: Challenges in the Treatment of CINV

July 17th 2017

EP. 2: Types of CINV

July 17th 2017

EP. 3: Classification of Emetogenicity of Chemotherapeutic Agents

July 17th 2017

EP. 4: Multidisciplinary Approach to Treating CINV

July 17th 2017

EP. 5: Patient Risk Factors in CINV

July 17th 2017

EP. 6: Patient Education Materials for CINV

July 17th 2017

EP. 7: Treating CINV Due to Immunotherapy and Targeted Therapy

July 17th 2017

EP. 8: Role of 5-HT3 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 9: Role of NK1 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 10: 5-HT3/NK1 Receptor Antagonist Combinations for CINV

July 17th 2017

EP. 11: Use of Olanzapine in CINV

July 17th 2017

EP. 12: Use of Dexamethasone in CINV

July 17th 2017

EP. 13: Unmet Needs in CINV

July 17th 2017
Advertisement
Advertisement

Trending on OncLive

1

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

2

Five Under 5: Top Oncology Videos for the Week of 6/28

3

TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC

4

Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera

5

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us